Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a definitive agreement to divest Sunosi® (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA), to Axsome Therapeutics (Nasdaq: AXSM).

Tue Mar 29 , 2022

Innovations in healthtech will keep evolving in the coming years. The rise in disposable income will increase the demand for high-quality healthcare and last-mile accessibility. The digital adoption index has suggested that the healthcare industry in India is embracing technological innovations at a much faster pace now than ever before. […]

Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics

Healthcare Innovations To Watch Out In 2022 & Beyond

Femtech Ultrasound AI company adds cloud-based solution, soniopedia

Tealium for Healthcare Builds Digital Trust with Patients and Physicians

Volta Medical, GE HealthCare partner on AI-driven electrophysiology tech

Regard Raises $61M to close the Clinical Insights Gap in Healthcare with leading AI solution

AI-powered automation platform for healthcare launches out of stealth with $3 million backing

Click TO Unsubscribe

Useful Link

Email Subscriber

Click To Data Request

Subscribe to our newsletter

You May Like

Click TO Unsubscribe

Useful Link

Email Subscriber

Social Media Icons

Click To Data Request

Subscribe to our newsletter